Maxalt

Pharmacological action

Selective agonist of serotonin 5-HT1D-receptor. Thanks to the stimulating action on these receptors has protivomigrenoznoe action.

Metabolized with the participation of MAO type A.

Statement

Relief of migraine with aura or without it.

Dosage regimen

When administered a single dose is 10 mg. If the headache is resumed after the initial relief of the attack, Maxalt can be taken repeatedly. Daily dose - 30 mg, the interval between doses - at least 2 hours

Patients receiving propranolol, recommended a single dose of Maxalt 5 mg daily dose - less than 15 mg.

The effectiveness of re-admission for the relief of the same attack in the absence of the effect of the initial dose has not been studied in controlled trials.

Side effect

From the central and peripheral nervous system: dizziness, drowsiness, weakness, fatigue, headache, decreased mental alertness, insomnia, hyperesthesia, tremor, ataxia, nervousness, confusion, blurred vision, rarely - fainting.

Cardio-vascular system: chest pain, palpitations, rarely - arterial hypertension.

From the digestive system: stomach pain, nausea, vomiting, dry mouth, diarrhea, dyspepsia.

On the part of the musculoskeletal system: neck pain, muscle stiffness, feeling of heaviness and stiffness in muscles, muscular weakness.

Dermatological reactions: skin erythema, pruritus, sweating.

Other: thirst, hot flashes.

Contraindications

Decompensated hypertension, coronary heart disease established, including angina pectoris, history of myocardial infarction, documented asymptomatic coronary artery disease, suspected coronary artery disease, Prinzmetal angina, concurrent therapy or a period of less than 2 weeks after treatment MAO inhibitors, hypersensitivity to Maxaltu.

Pregnancy and breastfeeding

There are no adequate and well controlled studies of safety during pregnancy Maxalta not performed, so the application is only possible in cases of extreme necessity. Use during lactation is not recommended, because is not known whether Maxalt from breast milk in humans.

In experimental studies have not revealed fetotoksicheskogo of Maxalta and negative impact on fertility. Excreted in breast milk in animals.

Cautions

Do not use in patients with basilar or hemiplegic migraine, and atypical for migraine headaches. Maxalt should be used only in patients with diagnosed migraine.

Should not be used at the same time other agonists of serotonin 5-HT1D-receptor.

Patients at risk for coronary heart disease (including hypertension, diabetes, smoking, presence of family history of severe coronary artery disease) before treatment needs to study the Maxaltom the cardiovascular system.

Clinical experience with Maxalta elderly patients is limited.

Between doses of ergotamine preparations and Maxalta should observe an interval of at least 6 hours

Maxalt can be no earlier than 2 weeks after treatment MAO inhibitors.

Safety of pediatric Maxalta not been studied, therefore, the use in patients younger than 18 years is not recommended.

Drug Interactions

When applied simultaneously with agonists of serotonin 5-HT1-receptor is a risk of hyperstimulation of the additive serotonin 5-HT1-receptors.

With the simultaneous use of MAO inhibitors may significantly increase the concentration of Maxalta in plasma with nitrates - the risk of coronary artery spasm.

While the use of propranolol increases the concentration of Maxalta in blood plasma.